AZD4547 is a potent, oral, highly selective inhibitor of FGFR1–3 with proven antitumour properties from preclinical studies [11–15], including work in FGFR2-amplified GC xenografts that demonstrated complete and prolonged tumour regression in several AZD4547-treated animals [12]. The gene discussed is FGFR2; the disease is neoplasm.